International Clinical Trial: A Phase 1. first-in-human. randomized study to assess the safety. tolerability. and PK of single (SAD) and multiple (MAD) ascending doses of oral MTAl-1025 in healthy participants

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ACTRN12626000920392) titled 'A Phase 1. first-in-human. randomized study to assess the safety. tolerability. and PK of single (SAD) and multiple (MAD) ascending doses of oral MTAl-1025 in healthy participants' on July 27.

Study Type: Interventional

Study Design: Purpose: Treatment Allocation: Randomised controlled trial Masking: Blinded (masking used) Type of endpoint: Safety/efficacy

Primary Sponsor: Montai Therapeutics, Inc.

Condition: Ulcerative colitis (UC) Ulcerative colitis (UC) Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon Inflammatory and Immune System - ...